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A new synthetic isothiocyanate (ITC) derivative, ethyl 4-isothiocyanatobutanoate (E-4IB), appeared to be an effective modulator of
cellular proliferation and potent inducer of apoptosis. In cooperation with cisplatin, this compound exerted synergistic effects in
human ovarian carcinoma A2780 cells. In the present study we investigated in more detail E4IB-sensitisation for cisplatin-induced
apoptosis. Sequential administration of both cytostatic agents led to increased intracellular platinum accumulation, glutathione level
depletion and mitochondrial membrane potential dissipation. These events were accompanied with poly (ADP-ribosyl) polymerase
cleavage, stimulation of caspase-3 activity, upregulation of p53, FasL and Gadd45a, cyclin B1 downregulation and an increase in
mitogen-activated protein kinases JNK, ERK and p38 phosphorylation as well as PI3K level alterations. The presented results might
have implications for developing new strategies aimed at therapeutic benefit of natural or synthetic ITCs in cooperation with various
anticancer drugs.
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Chemotherapy constitutes an essential approach of ovarian cancer
treatment. Combined sensitiser/inducer concept in specific se-
quence, aimed at bringing tumour cell populations into a state
where they are most susceptible to cytotoxic effects of chemo-
therapeutic agents, may be a novel strategy to enhance the efficacy
of anticancer therapy in a variety of human cancers (Sampath and
Plunkett, 2001; Schuchmann et al, 2006).
Cisplatin, one of the most potent antitumour agents with clinical
activity against a variety of solid tumours, had changed the course of
therapeutic management of these tumours (Zamble et al,1 9 9 8 ;
Cohen and Lippard, 2001). Cytotoxicity of cisplatin is mediated by
formation of DNA adducts as the key structures activating several
signal transduction pathways including MAPKs resulting in activa-
tion of apoptosis (Siddik, 2003; Wang and Lippard, 2005). Intensive
search for new compounds that could interfere with these pathways
can help to increase platinum efficacy (Abou El Hassan et al,2 0 0 4 ;
Wernyj and Morin, 2004; Rothermundt et al, 2006).
Naturally occurring isothiocyanates (ITCs) have been known to
be effective chemopreventive agents (Steinmetz and Potter, 1991)
and to exhibit a protective effect against cancers in a variety of
target organs (Morse et al, 1993; Hecht, 1995). Isothiocyanates
perturb several steps in the carcinogenic process by inhibiting cell
growth due to cell cycle arrest and removing premalignant and
malignant cells through the activation of apoptosis (Gamet-
Payrastre et al, 2000; Miyoshi et al, 2004; Pullar et al, 2004).
In the previous study (Bodo et al, 2006), we introduced a new
synthetic ITC-derivative, ethyl 4-isothiocyanatobutanoate (E-4IB),
as an efficient modulator of cell cycle and apoptosis. In search for
novel strategies to sensitise tumour cells, the objective of this study
was to describe further activities of E-4IB to render cisplatin-
induced apoptosis in human ovarian tumour cell line A2780. We
indicated that this ITC-derivative enhanced intracellular platinum
accumulation and conferred the cells a state of increased
responsiveness to cisplatin-induced apoptosis associated with
alterations in cell cycle protein regulation, glutathione (GSH)
levels, caspase-3 activation, mitochondrial potential and signalling
pathways including MAPKs family members.
MATERIALS AND METHODS
Reagents
E-4IB was synthesised as described (Floch et al, 1997). Dimethyl
sulphoxide (DMSO), RNase A, monochlorobimane (MCB) and
propidium iodide (PI) were obtained from Sigma Chemical Co. (St
Louis, MO, USA). Cisplatin was acquired from LACHEMA (Brno,
Czech Republic). Rabbit polyclonal antibodies against ERK1/2,
phospho-ERK1/2, JNK1/2, p38, FasL, actin, PARP, p21, p53,
Gadd45a, cyclin B1 and horseradish peroxidase-conjugated anti-
rabbit antibody were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit polyclonal anti-ACTIVE JNK- and
anti-ACTIVE p38 antibodies were purchased from Promega
(Medison, WI, USA). Cationic JC-1 dye was a product of Molecular
Probes (Eugene, OR, USA). Caspase substrate (Ac-DEVD) and
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scaspase inhibitor (Z-DEVD) were gained from Alexis (Lausen,
Switzerland).
Cell culture, drug treatments, clonogenic assay and
apoptosis
Human ovarian carcinoma cells A2780 were routinely cultured in
RPMI 1640 medium supplemented with 10% heat-inactivated FCS,
2m ML -glutamine, 100mgml
 1 penicillin and 50mgml
 1 strepto-
mycin. 0.5 10
6cellsml
 1 were cultured in 96-, 24- or six-well
plates (Greiner, Germany). Cells were incubated with E-4IB or
cisplatin at indicated concentrations and time determined by MTT
assay (Bodo et al, 2005). In combination, we used sequential
treatments with E-4IB followed by cisplatin, when E4IB was added
3h before cisplatin. Clonogenic growth after treatments for 7 days
was assessed by Giemsa-Romanowski staining and measured using
ImageJ 1.33u software (National Institutes of Health, USA).
Apoptosis was assessed by flow cytometric analysis of PI-stained
nuclei as previously described (Jakubikova et al, 2005).
Measurements of platinum accumulation
Flameless atomic absorption spectrophotometry (FAAS) was used
to analyse platinum levels in tested cells. Cultures were digested in
nitric acid followed by H2O2 and HCl addition. Flameless atomic
absorption spectrophotometry measurements were performed
with a Varian AA240Z Zeeman atomic absorption spectrometer
equipped with a GTA 120 graphite tube atomizer (Crul et al, 2001;
Pluim et al, 2004).
GSH assay
Cells were seeded in 96-well microplates (black wells with
transparent bottom) at a density of 5 10
3well
 1 and allowed to
adhere in the growth medium to 50–60% confluence before being
exposed to the tested drugs and buthionine-sulphoximine (BSO),
respectively, for 3, 6 or 27h in quadruplicates. After incubation
with MCB (40mM) in the dark, at room temperature for 20min and
several washings, samples were measured at 390/520nm (excita-
tion/emission) using the POLARstar fluorimeter (BMG Labtech
GmbH, Germany) (Kamencic et al, 2000).
Caspase-3 activity and mitochondrial potential
determination
Measurements of caspase-3 activity were performed with the use of
fluorescence technique as described (Moriya et al, 2000). Briefly,
3 10
6 washed cells were lysed in a buffer (pH 7.5) containing
50mM TRIS, 1mM EDTA, 10mM EGTA, 0.5 % Triton X-100 and
1m M DTT for 10min and samples were centrifuged at 10.000g for
10min. Cleared lysates (10mg of protein) containing 50mM of
substrate were incubated at 371C for 1h. An amount of released
AFC (7-amino-4-trifluoromethyl coumarin) was measured with the
POLARstar fluorimeter using excitation at 390nm and emission at
520nm.
Mitochondrial membrane potential (Cm) was assessed by JC-1
dye measurement of red/green fluorescence ratio as described
(Jakubikova et al, 2005). Briefly, cells were washed twice with PBS
and incubated with 400ml of PBS/0.2% BSA containing 4mM of JC-
1, at 371C for 30min. Fluorescence was measured by Coulter Epics
Altra flow cytometer. Data were analysed by the WinMDI version
2.8 software (J Trotter, Scripps Research Institute, La Jolla, CA,
USA).
Western blot analysis
To examine effects of E-4IB and cisplatin on membrane protein
expression, A2780 cells were harvested at indicated times, lysed in a
buffer as described (Bodo et al, 2006). For each lane 50mgo fp r o t e i n
were loaded. Blots were incubated with the indicated antibodies and
horseradish peroxidase-conjugated anti-rabbit secondary anti-
body (1:3000 diluted). All primary antibodies were used at final
concentration 1mgml
 1. Enhanced chemiluminescence (ECL,
Amersham Arlington Heights, IL, USA) was used for detection.
Expression of actin was used as a control for equal gel loading.
Statistical analysis
Statistical significance was analysed by Analysis of variance
(ANOVA) and post hoc (Tukey) tests.
RESULTS
Cell sensitisation and growth inhibition
In the recent paper (Bodo et al, 2005), we referred relatively low
cytotoxic activity of synthetic ITC E-4IB in human ovarian A2780
cells and tested it in combination with conventional cytotoxic drug
cisplatin. To study experimental conditions, we fixed treatment
dose- and time-schedule (2.5, 5mM E-4IB; 5, 10mM cisplatin, for 6
or 27h) and found that pretreatment of cisplatin with E-4IB (E-
4IB/cisplatin) induced apoptosis in a dose- and time-dependent
manner. We also observed that sequential treatment with E-4IB
followed by cisplatin yielded more apoptotic cells than cotreatment
with both compounds. In the present study we showed that E-4IB
cooperated with cisplatin to inhibit clonogenic tumour cell growth
(Table 1). To study E-4IB and cisplatin effects, experiments
revealed that cellular accumulation of platinum in combination
with E-4IB (E-4IB/cisplatin) is more than three-fold higher
(9.2870.69ng Pt/10
6 cells) than that observed with a single
cisplatin (2.9770.32ng Pt/10
6 cells) (Table 2).
Table 1 Effect of E-4IB on cisplatin-induced clonogenic survival
Concentration (lM)
Relative average
E-4IB Cisplatin Count
— — 1.0070.00
0.5 — 0.9170.06
1 — 0.7970.09
— 0.1 0.7470.05*
0.5 0.1 0.6470.11
1 0.1 0.4070.02
#
— 0.25 0.4370.08**
0.5 0.25 0.3270.02
1 0.25 0.1070.09
#
E-4IB¼ethyl 4-isothiocyanatobutanoate. A2780 cells were treated with 0.1 or
0.25mM cisplatin in the presence or absence of 0.5 or 1mM E-4IB. Clonogenic survival
was assessed by Giemsa-Romanowski staining after 7 days and colony numbers per
well of a six-well plate are indicated. Statistical significant differences from the
controls, *Po0.05, **Po0.01, and from the corresponding cisplatin-treated samples,
#Po0.05.
Table 2 Effect of E-4IB on platinum intracellular accumulation
Samples Control E-4IB Cisplatin E-4IB+cisplatin
ng Pt/10
6 cells 0.2970.04 0.3470.13 2.9770.32** 9.2870.69
##
E-4IB¼ethyl 4-isothiocyanatobutanoate; FAAS¼flameless atomic absorption spec-
trophotometry. A2780 cells were treated with 10mM cisplatin in the presence or
absence of 5mM E-4IB. Flameless atomic absorption spectrophotometry was used to
analyse platinum levels. Statistical significant differences from the controls, **Po0.01,
and from the cisplatin-treated samples,
##Po0.01.
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sGSH level alterations
In ovarian cancer cells, increased GSH levels have been correlated
directly with the drug resistance (Okuno et al, 2003). We
investigated therefore the capacity of A2780 ovarian cancer cells,
treated cells with E-4IB and/or cisplatin, to regulate GSH.
Experiments aimed at the testing of a single drug or sequential
treatments with E-4IB followed by cisplatin showed GSH decrease
in a dose- and time-dependent manner. Glutathione inhibition by
BSO was utilised as control (Figure 1A and B).
Caspase-3 activity and mitochondrial potential Wm
Fluorescence substrate (Ac-DEVD-AFC) detection test was used to
see whether sensitisation by E-4IB followed by cisplatin involves
caspase-3 activation. We found that caspase-3 is involved in a
single cisplatin treatment and its activity is increased at E-4IB/
cisplatin combination in a dose- and time-dependent manner
(Figure 2A). In addition, caspase-3 inhibition Z-DEVD technique
was used for the quantification of DCm. Incubation of cells in the
presence of E-4IB/cisplatin caused a significant reduction in Cm in
a dose-dependent manner and this was inhibited by Z-DEVD
(Figure 2B). Finally, we analysed the involvement of caspase-3 in
E-4IB sensitisation using Z-DEVD inhibitor. As observed by
detection of sub-G1 population measured by flow cytometry,
Z-DEVD significantly reduced E-4IB/cisplatin-induced apoptosis
(Figure 2C).
Modulation of apoptosis regulatory molecules
To gain further inside into the molecular mechanism(s) of
apoptosis regulation upon treatment with the studied drugs by
3 h 6 h 27 h
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Figure 1 (A) Modulation of GSH levels after E-4IB treatment. A2780
cells were exposed to 2.5 and 5mM E-4IB for 3, 6 and 27h. BSO (500mM)
was used as a control for GSH inhibition. (B) Cisplatin or E-4IB/cisplatin-
induced alterations in GSH levels. A2780 cells were exposed to E-4IB (2.5
or 5mM) for 3h followed by cisplatin (5 or 10mM) for 3 or 24h. The results
shown are representative of at least three independent experiments.
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Figure 2 (A) Activation of caspase-3 after E-4IB and/or cisplatin
treatment in A2780 cells. The cells were exposed to E-4IB (5mM) for 3h
followed by cisplatin (5 or 10mM). Caspase-3 activity was measured using
fluorogenic substrate Ac-DEVD-AFC. (B) Modulation of Cm. Caspase-3
inhibitor (Z-DEVD) was added to culture medium for 1h before the
exposure of the cells to 2.5 or 5mM E-4IB for 3h followed by cisplatin (5 or
10mM, for 3 or 24h). (C) Effect of Z-DEVD on the sub-G1 population in
the cells treated by E-4IB and/or cisplatin. Sub-G1 was calculated by flow
cytometry. The results are representative of at least three independent
experiments.
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sWestern blot analysis, we inspected several key molecules
associated with these events. Treatment with a single E-4IB
resulted in upregulation of FasL, but no PARP cleavage appeared
(Figure 3A). However, E-4IB significantly enhanced the ability of
cisplatin to induce PARP cleavage. Additionally, E-4IB/cisplatin
treatments led to the enhancement of FasL levels which culminated
at 5mM E-4IB/10mM cisplatin concentrations (Figure 3B).
Modulation of cell cycle regulation proteins
To study cell cycle protein alterations, we examined the levels of
cell cycle-responsive molecules such as cyclin B1, p53, p21 and
Gadd45a (growth arrest- and DNA damage-inducible protein).
Ovarian cells were exposed to E-4IB (Figure 4A) and/or cisplatin
(Figure 4B) and visualised by Western blotting. P53, p21 and
Gadd45a levels were enhanced by a single E-4IB treatment in a
time- and dose-dependent manner. On the contrary, cyclin B1
levels significantly dropped after E-4IB or E-4IB/cisplatin treat-
ments. Interestingly, after prolonged time (27h), abundant
amounts of p53 after cisplatin or E-4IB/ciplatin treatments were
determined. However, p21 levels culminated at the concentration
of 5mM cisplatin and then continuously decreased due to increased
cisplatin or E-4IB/cisplatin concentrations. Surprisingly, single
cisplatin treatments exerted no alterations in Gadd45a levels, but
these remained at similar levels as observed with a single E-4IB
(Figure 4A and B).
Protein kinases alterations
Alterations in the activities of the MAPKs and PI3K levels are
generally supposed to be associated with the control of cell
proliferation, differentiation and death (Wada and Penninger,
2004). In this context, after extracellular stimuli with E-4IB and/or
cisplatin, we assessed MAPKs activities to be linked with
phosphorylation and also measured PI3K alterations. Single E-
4IB administration (Figure 5A) exerted no influence on constitu-
tive ERK1/2 levels. However, upregulation of both constitutive and
phosphorylated MEK1, in a dose-dependent manner, was observed
and this correlated with an enhancement of ERK1/2 phosphoryla-
tion. Interestingly, no substantial alterations in constitutive JNK1/2
and p38 MAPK were determined, whereas phosphorylated p38
MAPK form rose. Contrariwise, 27h E-4IB/cisplatin treatment was
linked to an enhanced phosphorylation of both JNK and p38
MAPK. Conversely, MEK1, pMEK1, ERK1/2 and PI3K (phospha-
tidylinositol 3-kinase) contents were lowered (Figure 5B).
DISCUSSION
The major mode of cisplatin effect is mediated by interaction with
DNA to form DNA adducts and activation several signal
transduction pathways that culminate in a variety of tumour cell
lines in the cell growth arrest and apoptosis. In chemotherapy
cisplatin was utilised to cooperate with several anticancer
compounds to enhance efficacy of its antitumour activity generally
resulting in apoptosis (Reed, 1998; Roberts et al, 2005; Siegel-
Lakhai et al, 2005).
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Figure 3 Western blots of apoptosis-related proteins FasL and PARP.
A2780 cells were exposed to E-4IB (A) or cisplatin or E-4IB/cisplatin (B).
Experimental conditions were used as shown in Figure 1. Western blot
analysis was performed with total cell extracts. Fifty micrograms of cell
lysate was applied for FasL or PARP expression. Actin was utilised for equal
protein loading.
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Figure 4 Western blot analysis of A2780 cell protein extracts after E-4IB
(A), or cisplatin or E-4IB/cisplatin treatments (B). Cyclin B1, p53, p21 and
Gadd45a protein levels were evaluated. Experimental conditions were
used as shown in Figure 1.
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Figure 5 Western blot analyses of E-4IB (A) or cisplatin or E-4IB/
cisplatin (B). ERK1/2, pERK1/2, JNK1/2, pJNK1/2, p38, pp38, MEK1, pMEK1
and PI3K protein levels were determined. Cells were treated as shown in
Figure 1.
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compounds in chemotherapy we (Bodo et al, 2005) and others
(Fimognari et al, 2006) recently referred activities of ITCs as
‘sensitizers’ followed by conventional chemotherapeutic com-
pounds as ‘inducers’, to trigger inhibition of proliferation and
their synergy to stimulate apoptosis in cancer cells. We further
showed that the cytostatic activity of E-4IB was more pronounced
than its cytotoxic activity at equimolar concentrations. In the
present study, using the same experimental system, we confirmed
this synergy by clonogenic assay and investigated for the first time
signalling pathways due to their cooperative effect. We determined
that E-4B/cisplatin-induced apoptosis correlated with enhanced
intracellular platinum accumulation. These events were associated
with GSH depletion, downregulation of cyclin B1, mitochondrial
potential dissipation, PARP cleavage, p53-, Gadd45a- and p21-
upregulation, attesting to the specific effect of E-4IB sensitisation
for cisplatin-induced cell cycle alterations and apoptosis.
The mechanisms of cellular uptake and efflux of cisplatin are
still not fully understood. However, it was documented that
intracellular GSH and exporter proteins have an important role in
those processes, presumably by drug inactivation and drug efflux
promotion (Mistry et al, 1993; Wang and Lippard, 2005). In the
present study we found reduction of intracellular GSH in a dose-
dependent manner after E-4IB treatments. Thus, observed increase
of platinum intracellular accumulation stimulated by E-4IB
pretreatments could be explained by a decrease of GSH availability
to form cisplatin conjugates and thereby subsequent reduction of
cellular efflux of the drug.
It has been shown that activation of JNK leads to targeting of the
activator protein-1 (AP-1) transcription factor complex binding
sites in the promoters of multiple target genes such as FasL, an
element of death receptor-dependent apoptotic signalling cascade
(Le Niculescu et al, 1999). In this context, combination E-4IB and
cisplatin in our experimental conditions led to marked enhance-
ment in FasL levels. Thus, we also assume that FasL may play an
important role in initiation of E-4IB/cisplatin-induced apoptosis.
The molecular mechanisms for cisplatin-induced apoptosis
involved caspase-3 activation (Kolfschoten et al, 2002). To see an
importance of caspase-3, we inspected the activity of the enzyme
and demonstrated a time- and dose-dependent activation of
caspase-3 caused by single drug treatments or in combination.
Flow cytometric analysis aimed at the regulation of mitochondrial
potential and an appearance of sub-G1 portion of apoptotic cells
confirmed an essential role of this enzyme in E-4IB/cisplatin-
induced apoptosis.
Our results further showed marked increase in p53 levels after
cisplatin treatment, which, surprisingly, were not affected by E-4IB
sensitisation. These events were after E-4IB/cisplatin treatments
associated with moderate increase in Gadd45a protein levels. This
may suggest that E-4IB, concomitantly with Gadd45a (growth
arrest- and DNA damage-inducible protein), might contribute to
the transcription activation of p53. In fact, in response to
genotoxic stimuli, Gadd45a was shown to be increased and
participated in nucleotide excision repair thereby it sensitised
different tumours to undergo apoptosis (Sheikh et al, 2000). P53
and cdk inhibitor p21 have also been determined to maintain G2
arrest following DNA damage (Taylor and Stark, 2001). In
addition, some experimental data show that p21 blocks cell
cycle progression through its negative activity on various cyclin-
dependent kinases and apoptosis through inhibition of caspases
activation (Viallard et al, 2001). These events involve an initial
inhibition of cyclin B1/Cdc2 activity by p21 and a subsequent
reduction of cyclin B1 (Charrier-Savournin et al, 2004). In
relation to the reduction of cyclin B1 observed in our experiments
we assume that the diminution of p21 observed after E-4IB/
cisplatin combination treatments facilitate the cells to trigger
apoptosis.
Three MAPK members (JNK, ERK and p38) participate in
integrating extracellular signals to regulate cell proliferation,
differentiation, cell survival and apoptosis (Dent and Grant,
2001). The kinases were activated following exposure of tumour
cells to cisplatin, when ERK activation might be critical for
cisplatin-induced apoptosis (Persons et al, 2000; Yeh et al, 2002).
Furthermore, the duration of JNK- and p38 MAPK activation was
demonstrated as an early key determinant of cisplatin-induced
apoptosis (Sanchez-Perez et al, 1998; Benhar et al, 2001; Mansouri
et al, 2003; Kusama et al, 2006). In accordance with these results
we presented here sustained activation/phosphorylation of p38
MAPK and this was associated with E-4IB/cisplatin-induced
apoptosis.
Phosphatidylinositol 3-kinase is believed to be important cell
survival factor in human ovarian cancer cells (Asselin et al, 2001).
PI3K/AKT pathway facilitates G1 to Sphase progression and plays
a major role in protecting of cells from apoptosis by inhibiting Bad
and thus cytochrome c release, inactivating caspase-3 and targeting
p53 for its destruction (Kennedy et al, 1997). In our experimental
system we found continuous downregulation of PI3-kinase and, in
concordance with others, we assume that these events facilitate cell
cycle arrest and apoptosis as a consequence of E-4IB/cisplatin
treatment.
The presented results indicate the potential of E-4IB for
anticancer therapy may largely reside in its ability to sensitise
tumour cells to overcome cisplatin resistance and to induce
apoptosis. Thereby, our studies showed potential application of E-
4IB as sensitiser for cytotoxic therapies in ovarian cancer cells.
Finally, in terms of clinical perspective, the combined sensitiser (E-
4IB)/inducer (cisplatin) strategy may be a novel approach to
enhance the efficacy of anticancer therapy in some human cancers.
ACKNOWLEDGEMENTS
We gratefully acknowledge expert technical assistance by Ms Jana
Chovancova. This work was supported in part by Slovak
Governmental Research and Development sub-program Food-
quality and safety No. 2003SP270280E010280E01, Slovak Grant
Agency VEGA (No. 2/5042/25), European Social Fund (project
code 13120200038), National Program ‘Use of Cancer Genomics to
Improve the Human Population Health’, project 2003 SP
510280800/0280801.
REFERENCES
Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, Giaccone G, Kruyt
FA (2004) Overexpression of Bcl2 abrogates chemo- and radiotherapy-
induced sensitisation of NCI-H460 non-small-cell lung cancer cells to
adenovirus-mediated expression of full-length TRAIL. Br J Cancer 91:
171–177
Asselin E, Mills GB, Tsang BK (2001) XIAP regulates Akt activity and
caspase-3-dependent cleavage during cisplatin-induced apoptosis in
human ovarian epithelial cancer cells. Cancer Res 61: 1862–1868
Benhar M, Dalyot I, Engelberg D, Levitzki A (2001) Enhanced ROS
production in oncogenically transformed cells potentiates c-Jun N-
terminal kinase and p38 mitogen-activated protein kinase activation and
sensitization to genotoxic stress. Mol Cell Biol 21: 6913–6926
Bodo J, Chovancova J, Hunakova L, Sedlak J (2005) Enhanced sensitivity of
human ovarian carcinoma cell lines A2780 and A2780/CP to the
combination of cisplatin and synthetic isothiocyanate ethyl 4-isothio-
cyanatobutanoate. Neoplasma 52: 510–516
Cisplatin and E-4IB synergy
J Bodo et al
1352
British Journal of Cancer (2006) 95(10), 1348–1353 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sBodo J, Jakubikova J, Chalupa I, Bartosova Z, Horakova K, Floch L, Sedlak J
(2006) Apoptotic effect of ethyl-4-isothiocyanatobutanoate is associated
with DNA damage, proteasomal activity and induction of p53 and
p21(cip1/waf1). Apoptosis 11: 1299–1310
Charrier-Savournin FB, Chateau MT, Gire V, Sedivy J, Piette J, Dulic V
(2004) p21-mediated nuclear retention of cyclin B1-Cdk1 in response to
genotoxic stress. Mol Biol Cell 15: 3965–3976
Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer
chemotherapy. Prog Nucleic Acid Res Mol Biol 67: 93–130
Crul M, van den Bongard HJ, Tibben MM, van Tellingen O, Sava G,
Schellens JH, Beijnen JH (2001) Validated method for the determination
of the novel organo-ruthenium anticancer drug NAMI-A in human
biological fluids by Zeeman atomic absorption spectrometry. Fresenius J
Anal Chem 369: 442–445
Dent P, Grant S (2001) Pharmacologic interruption of the mitogen-
activated extracellular-regulated kinase/mitogen-activated protein kinase
signal transduction pathway: potential role in promoting cytotoxic drug
action. Clin Cancer Res 7: 775–783
Fimognari C, Nusse M, Lenzi M, Sciuscio D, Cantelli-Forti G, Hrelia P
(2006) Sulforaphane increases the efficacy of doxorubicin in mouse
fibroblasts characterized by p53 mutations. Mutat Res, in press
Floch L, Kuban J, Gogova A, Jakubik T, Pronayova N (1997) Synthesis of
ethyl 4-isothiocyanatobutanoate derivatives. Chem Pap-Chem Zvesti 51:
416–420
Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S,
Gasc N, Tulliez J, Terce F (2000) Sulforaphane, a naturally occurring
isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human
colon cancer cells. Cancer Res 60: 1426–1433
Hecht SS (1995) Chemoprevention by isothiocyanates. J Cell Biochem Suppl
22: 195–209
Jakubikova J, Bao Y, Sedlak J (2005) Isothiocyanates induce cell cycle
arrest, apoptosis and mitochondrial potential depolarization in HL-60
and multidrug-resistant cell lines. Anticancer Res 25: 3375–3386
Kamencic H, Lyon A, Paterson PG, Juurlink BH (2000) Monochlorobimane
fluorometric method to measure tissue glutathione. Anal Biochem 286:
35–37
Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN,
Hay N (1997) The PI 3-kinase/Akt signalling pathway delivers an anti-
apoptotic signal. Genes Dev 11: 701–713
Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM,
Boven E (2002) Time-dependent changes in factors involved in the
apoptotic process in human ovarian cancer cells as a response to
cisplatin. Gynecol Oncol 84: 404–412
Kusama T, Mukai M, Tatsuta M, Nakamura H, Inoue M (2006) Inhibition of
transendothelial migration and invasion of human breast cancer cells by
preventing geranylgeranylation of Rho. Int J Oncol 29: 217–223
Le Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M (1999)
Withdrawal of survival factors results in activation of the JNK pathway in
neuronal cells leading to Fas ligand induction and cell death. Mol Cell
Biol 19: 751–763
Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y,
Siddik ZH, Mills GB, Claret FX (2003) Sustained activation of
JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand
induction and cell death in ovarian carcinoma cells. J Biol Chem 278:
19245–19256
Mistry P, Loh SY, Kelland LR, Harrap KR (1993) Effect of buthionine
sulfoximine on PtII and PtIV drug accumulation and the formation of
glutathione conjugates in human ovarian-carcinoma cell lines. Int J
Cancer 55: 848–856
Miyoshi N, Takabayashi S, Osawa T, Nakamura Y (2004) Benzyl
isothiocyanate inhibits excessive superoxide generation in inflammatory
leukocytes: implication for prevention against inflammation-related
carcinogenesis. Carcinogenesis 25: 567–575
Moriya R, Uehara T, Nomura Y (2000) Mechanism of nitric oxide-
induced apoptosis in human neuroblastoma SH-SY5Y cells. FEBS Lett
484: 253–260
Morse MA, Zu H, Galati AJ, Schmidt CJ, Stoner GD (1993) Dose-related
inhibition by dietary phenethyl isothiocyanate of esophageal tumorigen-
esis and DNA methylation induced by N-nitrosomethylbenzylamine in
rats. Cancer Lett 72: 103–110
Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S,
Hamada H, Yoshikawa H, Kondo T, Bannai S (2003) Role of cystine
transport in intracellular glutathione level and cisplatin resistance in
human ovarian cancer cell lines. Br J Cancer 88: 951–956
Persons DL, Yazlovitskaya EM, Pelling JC (2000) Effect of extracellular
signal-regulated kinase on p53 accumulation in response to cisplatin.
J Biol Chem 275: 35778–35785
Pluim D, van Waardenburg RC, Beijnen JH, Schellens JH (2004)
Cytotoxicity of the organic ruthenium anticancer drug Nami-A is
correlated with DNA binding in four different human tumour cell lines.
Cancer Chemother Pharmacol 54: 71–78
Pullar JM, Thomson SJ, King MJ, Turnbull CI, Midwinter RG, Hampton MB
(2004) The chemopreventive agent phenethyl isothiocyanate sensitizes
cells to Fas-mediated apoptosis. Carcinogenesis 25: 765–772
Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and
platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:
331–344
Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton
TC, O’Dwyer PJ, Johnson SW (2005) Identification of genes associated
with platinum drug sensitivity and resistance in human ovarian cancer
cells. Br J Cancer 92: 1149–1158
Rothermundt C, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T,
Kaye S, Gore M (2006) Combination chemotherapy with carboplatin,
capecitabine and epirubicin (ECarboX) as second- or third-line
treatment in patients with relapsed ovarian cancer: a phase I/II trial.
Br J Cancer 94: 74–78
Sampath D, Plunkett W (2001) Design of new anticancer therapies targeting
cell cycle checkpoint pathways. Curr Opin Oncol 13: 484–490
Sanchez-Perez I, Murguia JR, Perona R (1998) Cisplatin induces a
persistent activation of JNK that is related to cell death. Oncogene 16:
533–540
Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM,
Siebler J, Weinmann A, Teufel A, Worns M, Fischer T, Strand S, Lohse
AW, Galle PR (2006) Histone deacetylase inhibition by valproic acid
down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards.
Oncol Rep 15: 227–230
Sheikh MS, Hollander MC, Fornance Jr AJ (2000) Role of Gadd45 in
apoptosis. Biochem Pharmacol 59: 43–45
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene 22: 7265–7279
Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A,
Solanki B, Beijnen JH, Schellens JH (2005) Phase I and pharmacological
study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777)
in combination with gemcitabine and cisplatin in patients with advanced
solid tumours. Br J Cancer 93: 1222–1229
Steinmetz KA, Potter JD (1991) Vegetables, fruit, and cancer. I.
Epidemiology. Cancer Causes Control 2: 325–357
Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53.
Oncogene 20: 1803–1815
Viallard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J (2001) Molecular
mechanisms controlling the cell cycle: fundamental aspects and
implications for oncology. Cancer Radiother 5: 109–129
Wada T, Penninger JM (2004) Mitogen-activated protein kinases in
apoptosis regulation. Oncogene 23: 2838–2849
Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer
drugs. Nat Rev Drug Disc 4: 307–320
Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance:
still searching for the Achilles’ heel. Drug Resist Update 7: 227–232
Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL (2002) Increase of
the resistance of human cervical carcinoma cells to cisplatin by
inhibition of the MEK to ERK signalling pathway partly via enhancement
of anticancer drug-induced NF kappa B activation. Biochem Pharmacol
63: 1423–1430
Zamble DB, Jacks T, Lippard SJ (1998) p53-Dependent and -independent
responses to cisplatin in mouse testicular teratocarcinoma cells. Proc
Natl Acad Sci USA 95: 6163–6168
Cisplatin and E-4IB synergy
J Bodo et al
1353
British Journal of Cancer (2006) 95(10), 1348–1353 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s